CME-Directory

Description: Overview and Purpose The 10th International Congress on the Future of Breast Cancer is an educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be discussed, and controversial issues will be debated. In addition, strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and targeted therapies will be presented, and evolving diagnostic approaches to identify the driving mutations or pathways in breast cancer will be thoroughly discussed along with the therapies targeting those mutations. Controversial issues in the surgical and radiotherapeutic management of breast cancer will also be discussed and debated. The format will include didactic sessions, question-and-answer panel discussions, and ample time for participant interaction with faculty. Target Audience This educational activity is directed toward medical oncologists interested in the treatment of patients with breast cancer. Surgical and radiation oncologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to attend. Learning Objectives At the conclusion of this congress, you should be able to: Determine optimal surgical care for patients with breast cancer Incorporate recent advances in radiation therapy into the treatment of patients with breast cancer Integrate biomarkers, genomic assays, and other risk assessment tools into treatment decision making for breast cancer Employ optimal strategies for endocrine therapy and management of bone health for patients with hormone receptor–positive breast cancer Identify appropriate strategies for the use of cytotoxic agents in the treatment of patients with early-stage and advanced/refractory breast cancer Design treatment strategies for patients with HER2-overexpressing breast cancer, including novel agents, combinatorial therapies, and options for patients who progress on standard therapy Utilize targeted agents in the treatment of HER2– breast cancer Select eligible patients with breast cancer for promising clinical trials

Location: ,

Credit Hours: